Skip Navigation

Link to  the National Institutes of Health  
The Science of Drug Abuse and Addiction from the National Institute on Drug Abuse Archives of the National Institute on Drug Abuse web site
Go to the Home page

Director's Report to the National Advisory Council on Drug Abuse
February, 2002


On September 10-11, 2001, Ms. Beverly Jackson, Chief, Public Information and Liaison Branch, OSPC, and other members of the Branch held a meeting of the Public Information Officers of the Clinical Trials Network (CTN) in Arlington, Virginia. Approximately 20 grantee institutions from the CTN were represented. This conference included briefings by NIDA officials regarding the CTN concept, progress reports on the CTN, discussions about outreach projects for the media in all regions of the country, and how to stimulate effective communication between NIDA and others in the network.

NIDA hosted its 7th Constituent Conference, Blending Research and Practice, at the Westfields Marriott in Chantilly, Virginia, December 3-4, 2001. The Constituent Conference provides NIDA and constituent organization leaders with the opportunity for dialog and gives NIDA the chance to receive and respond to the concerns and research recommendations from the field. Dr. Glen R. Hanson, NIDA Acting Director, opened the conference with an update to constituent representatives on NIDA's research, new initiatives, achievements, and future directions since NIDA's last constituent conference in December 1999. A number of NIDA Division and Office Directors also presented on their specific research portfolios, followed by a facilitated discussion. In addition, several of NIDA's constituent representatives presented on activities their organizations are involved in and gave examples regarding actions they have taken to blend research and practice. Also, for the first time, NIDA used an automated response system to gain instant feedback from constituents on a number of areas concerning NIDA research and dissemination activities.

The Special Populations Office organized NIDA’s first health disparities conference to address drug abuse research in ethnic minority populations. The conference, Bridging Science and Culture to Improve Drug Abuse Research in Minority Communities, was held September 24-26, 2001, in Philadelphia, Pennsylvania. The conference provided a forum for over 450 researchers, practitioners, community providers, and others to share research needs, concerns, and opportunities. Plenary sessions and workshops covered such topics as treatment, epidemiology, interaction of culture, race, ethnicity and science, pharmacological and behavioral treatments with minority clients, prevention and treatment in correctional settings, challenges of minority and majority researchers and grants development. Additionally, 25 NIDA staff conducted roundtables on various NIDA programs, research opportunities and areas of drug abuse research. NIDA staff and extramural researchers from work groups were instrumental in the overall planning of the conference.

On November 10, 2001, at the Annual Society for Neurosciences meeting held in San Diego, CA, NIDA (along with NINDS) sponsored a satellite meeting titled, Translation of Genetic Research to Pain Treatment. This symposium highlighted the development of molecular biology-based treatments for pain. Four speakers, all NIDA grantees, presented their latest findings on the use of genetic research in the development of new pain treatments. Drs. David Yeoman (Stanford), Li-Yen Huang (University of Texas) and Andrew Mannes (University of Pennsylvania) discussed their findings concerning how gene therapy may be useful in the treatment of various types of pain. Dr. Jeffery Mogil (University of Illinois) discussed how genetic techniques might be used to identity new targets for pharmaceutical and gene therapy. Overall, this symposium showed how findings from molecular biology might be translated into treatments for pain. The co-chairs of this session were Dr. Dave Thomas, DNBR, NIDA and Dr. Robert Caudle, University of Florida.

Drs. David Shurtleff, OD, DNBR, Steve Grant, CNB, DTR&D, Minda Lynch, BCSRB, DNBR and Jerry Frankenheim, PICNRB, DNBR chaired a symposium entitled Neuroscience Perspectives on the Effects of Ecstasy (MDMA) at this year’s Society for Neuroscience annual meeting in November. The evening session overviewed findings on MDMA-induced neurotoxicity from preclinical and clinical investigations, and compared cellular mechanisms of action to the effects of other psychostimulants. New data on the persistence of psychological and cognitive consequences seen with repeated abuse were also discussed. Presentations were delivered by Dr. Glen Hanson of NIDA, Dr. Brian Yamamoto from Case Western University, Dr. Annette Fleckenstein from the University of Utah, Dr. Linda Chang from Brookhaven National Laboratory, and Dr. Michael Morgan from the University of Sussex in the U.K.

Drs. Karen Skinner, and Jonathan D. Pollock, DNBR, organized a satellelite symposium at the 2001 Annual Meeting of the Society for Neuroscience, entitled, Microarray Research - Evolving Standards that was held on November 9, 2001 at the San Diego Convention Center. Microarray technology allows you to profile the expression of genes in any tissue. This satellite symposium addressed the issue of developing standards for microarray research so that results can be compared among laboratories. The second part of the meeting was a mini-symposium on the technical challenges of microarray analysis of human post-mortem brain tissue that included Drs. Francine Benes, James Eberwine, Deborah Mash, Christine Konradi, and Giulio Pasinetti.

Drs. David Shurtleff, Steve Grant and Herb Weingartner, DNBR, chaired a NIDA-sponsored symposium at the annual meeting of the Society for Neuroscience entitled The Role of Frontal Cortex in Drug Addiction: Current Knowledge and Future Directions. Invited speakers included: Marina E. Wolf, Ph.D., Anthony A. Grace, Ph.D., Linda Porrinio , Ph.D., Deborah A. Yurgelun-Todd, Ph.D., Hugh Garavan, Ph.D., Antoine Bechara, Ph.D., Mark D’Esposito, Ph.D., and Trevor Robbins, Ph.D.

NIDA’s Women and Gender Research Group presented a poster, Gender Matters in Neuroscience Investigations of Drug Abuse at the annual meeting of the Society for Neuroscience, San Diego, CA, November 10-15, 2001.

Dr. Jonathan D. Pollock, DNBR and Dr. Eric Nestler, UT Southwestern organized a workshop at the 2001 American College of Neuropharmacology, entitled, Dendritic Morphology and Neuropsychopharmacology: Overview of Molecular Mechanisms, held at the Hilton Waikoloa Village on the Big Island of Hawaii, December 11, 2001. The purpose of this workshop was to discuss possible mechanisms underlying the increases in dendritic spine density, specifically in nucleus accumbens medium spiny neurons and prefrontal cortical pyramidal neurons after long-term exposure to the psychostimulants cocaine and amphetamine that have been suggested to mediate sensitized responses to these drugs even after prolonged periods of withdrawal. The workshop participants included Drs. Paul Worley, Betty A. Eipper, Liquin Luo, and Rafael Yuste.

Drs. Thomas Aigner and Roger Brown, DNBR, co-chaired a session at the 40th Annual Meeting of the American College of Neuropsychopharmacology in Waikoloa, HI, December 9-13, 2001. The session was entitled Functional Brain Imaging in Animals: Implications for Drug Abuse.

Dr. Nancy Pilotte, DNBR, organized Intracellular Protein Trafficking and Drugs of Abuse at the NIH, January 7-8, 2002. Speakers included: J. Benovic, R. Edwards, R. Elde, A. Fleckenstein, A. Galli, S. George, G. Hanson, L-Y Liu-Chen, R. Mains, H. Melikian, M. Robinson, A. Sorkin, T. Sudhof and M. von Zastrow.

Jag H. Khalsa, Ph.D., Paul Coulis, Ph.D., Sander Genser, M.D., M.P.H., and Henry Francis, M.D. of CAMCODA planned, organized and presented an outstanding workshop on: Interventions for Metabolic and Endocrine Complications of HIV/AIDS and Drug Abuse November 26-27, 2001 at Natcher Building, NIH Campus, Bethesda. A group of nationally and internationally known clinicians and scientists presented current research and made recommendations for future research on the subject. A brief summary is in preparation for the NIDA website. The proceedings will be published in Clinical Infectious Diseases.

A National CTN Steering Committee Meeting was held January 28-30, 2002, in Charleston, South Carolina.

The 51st biannual meeting of the Community Epidemiology Work Group (CEWG), chaired by Nicholas J. Kozel, DESPR, was held in San Diego, California on December 11-14, 2001. The CEWG is composed of researchers from 21 metropolitan areas of the United States who meet semiannually to report on patterns and trends of drug abuse in their respective areas, emerging drugs of abuse, vulnerable populations and factors that may place people at risk, and negative health and social consequences related to drug abuse. Reports are based on a variety of drug abuse indicator data, such as morbidity and mortality information, treatment data and local and State law enforcement data. Additional sources of information include criminal justice, correctional, medical and community health data, local and State survey information, and findings from focus groups and qualitative research studies.

The following are highlights from the meeting:

Cocaine/Crack - Although still at high levels, cocaine/crack indicators decreased in 10 CEWG areas, remained stable or mixed in 9, and increased in only 2 (Atlanta and Seattle). As crack use has decreased, powder cocaine has become more available in some CEWG areas including Denver, Miami/South Florida, Phoenix, and Washington, D.C.

Heroin - Heroin use indicators increased in 15 CEWG areas, remained stable in 2, and decreased in 4. Decreases were reported in Honolulu, Los Angeles, San Francisco, and Seattle, areas in which Mexican black tar is the primary type of heroin available. Areas located on the east coast, including Boston, New York, Newark, and Philadelphia, report that heroin is relatively cheap, widely available, and of high purity.

Other Opiates - Indicators of the illicit use of prescription semi-synthetic narcotic drugs, such as oxycodone and hydrocodone, increased in the 14 CEWG areas that reported on these drugs. Oxycodone emergency department (ED) mentions were highest in Philadelphia (195), Boston (122), and Seattle (94). The Massachusetts Department of Public Health drug lab reported 374 oxycodone samples in 2000 (145 in the Boston area). It was also reported that oxycodone could be purchased near methodone clinics in Washington, D.C. In 2000, there were 52 deaths involving hydrocodone and 8 involving oxycodone in Texas.

Marijuana - Marijuana use indicators increased in 12 CEWG areas, remained stable or mixed in 8, and decreased in 1 (Atlanta). Although marijuana ED mentions, arrests, and treatment admissions have been increasing, there is reportedly less stigma associated with the use of this drug than in prior years, and it is widely available in all CEWG and surrounding areas. In 2000, high proportions of clients entering drug treatment programs in Denver (42.4 percent), New Orleans (29.2 percent), St. Louis (27.5 percent), New York (25.4 percent), and Atlanta (21.1 percent) reported marijuana as their primary drug of abuse. In 2001 Minneapolis/St. Paul reported that 22.9 percent of treatment admissions were for primary marijuana abuse.

Methamphetamine - Methamphetamine use indicators increased in 6 (Denver, Honolulu, Los Angeles, Phoenix, San Diego, and Seattle) of the 7 CEWG areas that have relatively high rates of ED methamphetamine mentions and/or high percentages of methamphetamine (primary drug of abuse) treatment admissions. The 7th, San Francisco, was the only one reporting a decrease in methamphetamine indicators in 2000–2001. Increases in methamphetamine indicators were also reported in Atlanta, Minnesota/St. Paul, St. Louis, and cities in Texas. Other CEWG areas such as Chicago, Detroit, New York, Philadelphia, and Washington, D.C. reported increases in methamphetamine availability and use but still at low levels.

Club Drugs - MDMA (ecstasy) indicators increased in 18 CEWG areas and remained stable (at low levels) in 3—Baltimore, New Orleans, and Newark. Although the numbers of MDMA ED mentions are still small compared with those for other drugs, they have been increasing dramatically in most CEWG areas. The Benelux countries of Belgium, the Netherlands, and Luxembourg have been the main sources of MDMA in this country. There have been reports of attempts to establish clandestine labs capable of producing MDMA in CEWG sites, including Minneapolis, San Diego and in areas in Michigan and South Florida. The drugs produced in these labs are adulterated with many different substances. Pills sold as ecstasy were found to contain mixtures of a variety of chemicals/substances, making them more dangerous to use; some do not contain any of the precursors needed to produce MDMA.

PCP - PCP indicators were reported in 14 CEWG areas. In 2000, PCP ED mentions were especially high in Chicago (n = 1,003) and relatively high in Washington, D.C. (317), Dallas (120), and St. Louis (98). Los Angeles reported 51 PCP-involved deaths in 2000. Only a small number of ADAM arrestees tested positive for PCP

Impact of September 11, 2001 Events
Washington, D.C Immediately following the terrorist attacks on September 11th, heroin, cocaine, marijuana, and MDMA became less available in areas of the District. While drug trafficking was disrupted, drug market activity increased when police were diverted to other areas of the city.
New York City Since the World Trade Center attacks, areas of New York City have reported a shortage of heroin and other drugs. Bags of heroin are reported to contain less of the drug.

A CTN Annual Meeting was held September 10-13, 2001, in Arlington, Virginia. This was an opportunity to bring together researchers and practitioners that participate in the CTN to meet each other, network and interchange ideas and experiences. Multiple break out meetings were held for professional development and training. The meetings were cut short by the September 11th disasters.

On October 22-24, 2001, the CTN Steering Committee met in Bethesda, MD. The members discussed future funding plans for new nodes, agreed on a common assessment battery instrument for all future CTN trials, approved new protocol teams, and met with managed health care providers.

The CTN held its quarterly meeting of the Data & Safety Monitoring Board on Oct. 29, 2001 (postponed from Sept 17). The Board reviewed 6 current trials for safety and scientific integrity. Reports were presented on all Serious Adverse Events, and on the 6 trials’ progress. No protocol changes were recommended. Discussion will continue on procedures for reviewing new protocols.

During the months of August – December, over 160 conference calls were held in the CCTN. These conference calls were held by national committees, subcommittees, and work groups within the network.

Mr. Richard A. Millstein, NIDA Deputy Director, met with Drs. Joseph Autry, Acting Administrator, SAMHSA, and Ruth Sanchez-Way, Director of CSAP, on collaborations on prevention research and practice, October 10, 2001, Rockville, MD. A followup meeting of Mr. Millstein, Drs. Elizabeth Robertson and Jackie Kaftarian of DESPR, and Dr. Sanchez-Way and staff was held on February 11, 2002.

Mr. Millstein gave two talks at the annual meeting of the American Public Health Association on “Drug Abuse Research: The Foundation for Policy” and “Bringing Research Knowledge to Community Practice,” October 22-24, 2001, Atlanta, GA.

Mr. Millstein presented to the National Hispanic Science Network on “PAs, RFAs, and Strategies for Successful Grant Writing,” November 8, 2001, Washington, D.C.

Mr. Millstein presented on DESPR programs and priorities at NIDA’s 7th Constituent Conference, December 3, 2001, Chantilly, VA.

Mr. Millstein spoke to Leadership Montgomery on “What Science Tells Us About Drug Abuse”, December 5, 2001, Gaithersburg, MD.

Dr. Timothy P. Condon, Associate Director, NIDA, presented and was a discussant at the Club Drug Use and Gay Men’s Health Colloquium of the American Psychological Association Convention in San Francisco, CA on August 24, 2001.

Dr. Timothy P. Condon presented “Addiction as a Brain Disease: New Implications for Research and Practice” for the Connecticut Statewide Addiction Medicine/Psychiatry Grand Rounds interactive web broadcast on September 20, 2001.
Dr. Timothy P. Condon presented “Blending Research and Practice: What Research Can Tell Us” at the Demand Treatment! Leadership Institute II in Denver, Colorado on September 24, 2001.

Dr. Timothy P. Condon briefed two American Managed Behavioral Healthcare Organization member groups on the effectiveness of drug addiction treatment and on NIDA’s Clinical Trials Network on October 17, 2001 in Washington, D.C.

Dr. Timothy P. Condon presented and led discussions on club drugs, the science of addiction, and drug abuse prevention and treatment strategies during a half day symposium entitled “Science Advances in the Emerging Drug Problem: Blending Research and Practice” at the Alcohol and Drug Abuse Division of the State of Hawaii Department of Health Conference in Honolulu, HI on October 23, 2001.

Dr. Timothy P. Condon presented “Developmental Consequences of Prenatal Exposure to Drugs of Abuse” at the Intrauterine Effects of Substances of Abuse Institute of the 48th Annual Meeting of the American Academy of Child & Adolescent Psychiatry on October 24, 2001 in Honolulu, HI.

Dr. Timothy P. Condon presented “Advances in Drug Abuse and Addiction Research: Implications for Criminal Justice Populations” at the Eighth National TASC Conference on Drugs and Crime on October 30, 2001 in Orlando, FL.

Drs. Timothy P. Condon, OSPC, and Jerry Flanzer, DESPR, participated in Proposition 36: A Working Meeting on Research on November 9, 2001 in San Francisco, CA.

Dr. Timothy P. Condon participated in the Robert Wood Johnson Foundation Substance Abuse Policy Research Program Annual Grantee Meeting on November 14, 2001 in St. Augustine, FL.

Dr. Timothy P. Condon participated in the 2001 National Conference on Tobacco OR Health on November 27, 2001 in New Orleans, LA.

Dr. Timothy P. Condon presented an “Update on Research Dissemination” at NIDA’s Seventh Constituent Conference in Chantilly, VA on December 4, 2001.

Dr. Timothy P. Condon presented “Drug Abuse & Addiction: What’s New on the Research Scene” at the CADCA National Leadership Forum XII on December 13, 2001 in Washington, D.C.

Dr. Jack Stein, Deputy Director, OSPC, participated in a plenary session “Practice Improvement: Bridging the Gap Between Practice and Research” at the Alcohol & Substance Abuse Providers of New York State 5th Annual Treatment Prevention Conference in Saratoga Springs, New York on October 23, 2001.

Dr. Jack Stein conducted a half-day workshop on club drugs at the Annual Department of Education’s Alcohol and Drug Abuse Forum in Crystal City, Virginia on November 8, 2001.

Dr. Jack Stein and Dr. Jerry Frankenheim, DNRB, conducted a workshop entitled “MDMA (Ecstasy) What Research is Telling Us” at the CADCA National Leadership Forum in Washington, DC on December 14, 2001.

Dr. Cindy Miner, Chief, Science Policy Branch, OSPC, organized and presented “NIDA/NIMH Grantwriting Workshop and Mock IRG Panel” along with Dr. Cheryl Boyce, NIMH, at the American Academy of Child and Adolescent Psychiatry meeting, Friday, October 26, 2001 in Honolulu, Hawaii. This workshop was designed to familiarize child and adolescent psychiatrists with the NIH grants and review process.

Dr. Cindy Miner gave a presentation on club drugs for the Gerber Adult Seminars, Science and Technology series on November 19, 2001 at the Jewish Community Center, Rockville, Maryland.

Dr. Cindy Miner organized and presented along with Dr. Howard Kurtzman, NIMH, a grantwriting workshop at the annual meeting of the Gay and Lesbian Medical Association in New Orleans, LA, September 29, 2001.

Dr. Cindy Miner presented “Prescription Drug Misuse, Abuse and Addiction” at the CADCA National Leadership Forum, December 13, 2001, Washington, D.C.

Dr. Lula Beatty, Chief, Special Populations Office, presented a seminar on research opportunities at NIDA at George Washington University for students and faculty on November 2, 2001.

Dr. Lula Beatty presented a session on research funding opportunities at NIDA as part of the colloquia series at the School of Social Work, Howard University, on Nov. 19, 2001.

Dr. Lula Beatty presented a session on "Steps to NIH Support" at a meeting sponsored by the NIH Office on AIDS entitled "HIV/AIDS Prevention, Care and Research: Gathering for the Circle of Life" in Albuquerque on January 10, 2002.

In December 2001, Dr. Lula Beatty reviewed convention proposal submissions for Divisions 35 (Society for the Psychology of Women) and 45 (Society for the Psychological Study of Ethnic Minority Issues) of the American Psychological Association.

In September 2001, Dr. Lula Beatty reviewed conference proposal submissions for the Sixth National Head Start Research Conference.

Ana Anders, Senior Advisor on Special Populations, worked with ONDCP, other Federal Agencies (SAMHSA, Dept. of Education, Justice Dept., Dept. of Transportation, etc.) and representatives of the Mexican government on the planning of the U.S./Mexico Binational Drug Demand Reduction annual conference held in Mexico City, Mexico in November 2001. She was responsible for planning and co-chairing the pre-conference Research Symposium. Additionally, she planned and developed research workshops for the Conference Research Track.

Ana Anders participated in planning the 2001 national observance of World Health Day with the American Association for World Health, the Pan American Health Organization and other Federal agencies.
Ana Anders co-chaired the planning meeting for the Latino Behavioral Health Institute annual conference held in Los Angeles, California in September 2001.

Ana Anders, as the NIDA Project Officer of a contractual agreement with the University of Miami, participated in the planning and development of the first national conference of the National Science Network on Drug Abuse held in Washington, D.C., November 2001

Ana Anders, as President of the NIH Hispanic Employee Organization, planned and hosted the Hispanic Heritage Month Observance for the NIH in September 2001.

Flair Lindsey, Program Analyst, Special Populations Office, coordinated the fifth annual Summer Research with NIDA program. The program allowed high school and undergraduate students to engage in drug abuse research with NIDA grantees for 8-10 weeks during the summer. In 2001, 40 students and 17 grantees participated in the program.

On September 24-26, 2002, Mary Ann Stephens, Ph.D., CCTN, attended and hosted sessions at the Health Disparities Conference in Philadelphia, PA.

Dr. Jack Blaine, CCTN, gave a presentation on the CTN at the American Methadone Treatment Association Conference, October 7, 2001, in St. Louis, MO. At that same meeting, several CTN community treatment providers discussed the clinical treatment provider perspective on participating in research and CTN principal investigators discussed overcoming barriers to blending clinical practice and research.

Dr. Betty Tai, CCTN, presented on CTN efforts in outreach to Hispanic patient populations and future collaborations with the National Hispanic Science Network on Drug Abuse, November 8-10, 2001, in Washington, D.C., co-sponsored by the Puerto Rico/Virgin Island ATTC.

Dr. Mark Swieter, OEA, presented a talk in November at American University in Washington, DC. This talk, addressed to graduate students and faculty in a variety of scientific areas, covered NRSA fellowships, the grants process, and the “do’s and don’ts” of putting together an application.

Dr. Rita Liu, Associate Director for Receipt and Referral, OEA, and co-chair of the NIDA Neuroscience Consortium Workgroup, assisted in the organization of a poster session on NIDA program priorities and review issues at the November meeting of the Society for Neuroscience in San Diego. The Office of Extramural Affairs was represented by Drs. Teresa Levitin, Director, OEA; Khursheed Asghar, Chief, Basic Sciences Review Branch; and Rita Liu.

Mr. Richard Harrison, Chief, Contracts Review Branch, OEA, provided information and recruitment activities with a NIDA Exhibit Booth for American Indian students at the November meeting of the American Indian Science and Engineering Society held in Albuquerque, NM.

Dr. William C. Grace served as a reviewer for HIV research proposals for the National Institute of Allergy and Infectious Diseases Prevention Science Review Committee in November.

Drs. William C. Grace, Deputy Director, OEA, Teresa Levitin, Director, OEA, and Susan Coyle, (formerly of OEA) presented “Characteristics of Successfully Recruited Grant Application Peer Reviewers” at the Fourth International Congress on Peer Review in Biomedical Publication held in Barcelona, Spain, September 14-16, 2002. Since air travel disruption precluded the authors’ attendance at this meeting, a poster session displaying their data was presented on their behalf.

Dr. Marina Volkov, SRA, Clinical, Epidemiological, and Applied Sciences Review Branch, OEA, presented a talk at City College of the City University of New York. Her talk was titled "Navigating the Bureaucratic Haze: How to Get Funding from NIH," and it was presented on December 10, 2001.

Dr. Minda Lynch, BCSRB, DNBR presented on “Club Drugs” to the Montgomery County Alcohol and Other Drug Abuse Advisory Council in January 2001.

Dr. Cora Lee Wetherington, DNBR and NIDA’s Women & Gender Research Coordinator, gave the keynote talk, “Developmental Vulnerabilities for Women and Substance Abuse,” in the workshop, “ Women and Substance Abuse” at the California Society of Addiction Medicine: State of the Art in Addiction Medicine meeting in Marina Del Rey, CA, October 19, 2001.

Dr. Cora Lee Wetherington served as co-host of the Women and Drug Abuse Special Interest Luncheon Table at the National Hispanic Science Network on Drug Abuse first national conference, Hispanic Drug Abuse Research: Advancing the Field, November 8-10, 2001, Washington, DC.

A NIDA sponsored Workshop; “Using Buprenorphine in Office-Based Practice” was held on Monday October 8, 2001 at the American Methadone Treatment Association Meeting in St. Louis, Missouri. This session was organized by Drs. Dorynne Czechowicz, Robert Walsh and Frank Vocci, all of NIDA’s Division of Treatment Research and Development.

NIDA sponsored a symposium on the prevention and treatment of adolescent drug abuse at the ASAM state-of –the art conference in November 2001, Washington, D.C. This session was organized by Dorynnne Czechowicz, M.D., DTR&D, in collaboration with the NIDA Child and Adolescent Research Workgroup.

On November 16, 2001, at the Association for Advancement of Behavior Therapy meeting in Philadelphia, Dr. Lisa Onken, DTR&D, discussed “Writing Behavioral Treatment Research Grants for NIDA“ at a symposium organized by Steven Beach, Ph.D. on “Writing Grants for NIDA, NIMH, and the CDC.”

On November 17, 2001, at the Association for Advancement of Behavior Therapy meeting in Philadelphia, Dr. Lisa Onken, DTR&D, participated in a symposium organized by Linda Dimeff, Ph.D. entitled, “Getting It Out There In A Big Way: Three National Models of Dissemination.” Her presentation was on “Behavioral Treatment Research at NIDA.”

Debbie Grossman and Dr. Ivan Montoya, both of DTR&D, represented NIDA at the Youth Tobacco Cessation Collaborative Meeting (YTCC) in Washington, D.C., on December 11, 2001. The YTCC is a collaborative group composed of representatives of major organizations that fund research, program, and policy initiatives related to controlling youth tobacco use.

Robert Walsh, DTR&D, presented “Studying Buprenorphine in Office-Based Settings NIDA/VACSP Study #1018”at the NIDA sponsored workshop entitled “Using Buprenorphine in Office-Based Practice” on October 8, 2001, at the American Methadone Treatment Association Meeting in St. Louis, Missouri. Dr. Dorynne Czechowicz, Mr. Robert Walsh and Dr. Frank Vocci, DTR&D organized this session.

Dr. Steven Grant, DTR&D, co-chaired a satellite symposium with Drs. David Shurtleff and Herb Weingartner entitled “Neuroscience Perspectives on the Effects of Ecstasy (MDMA)” at the 31st annual meeting of the Society for Neuroscience, San Diego, California November 14, 2001. Speakers at the symposium were Brian Yamamoto, Cleveland VA Medical Center, Annette Fleckenstein, University of Utah, Linda Chang, Brookhaven National Laboratory, Michael Morgan, University of Wales and Glen Hanson, NIDA.

Drs. Steven Grant, Harold Gordon, and Joseph Frascella represented the Clinical Neurobiology Branch, DTR&D at the NIDA booth during the Society for Neuroscience Meeting in San Diego, CA, November 12-15, 2001.

Drs. Joseph Frascella and Frank Vocci, DTR&D, conducted a session entitled “Strategies for Successful Grant Writing” at the First National Conference Hispanic Drug Abuse Research: Advancing the Field held in Washington, DC, November 8, 2001.

Dr. Joseph Frascella, DTR&D, presented a poster on the Institute’s Clinical Neurobiology program at a symposium of the 31st annual meeting of the Society for Neuroscience entitled “Transition from Drug Use to Addiction: Neuroscience Advances and Opportunities”, November 13, 2001 in San Diego, CA.

Dr. Steven Grant, DTR&D, co-chaired a symposium with Charles O’Brien, M.D., Ph.D. (University of Pennsylvania) entitled “Transition to Addiction: Does Pushing the Lever Pull the Switch” at the 40th annual meeting of the American College for Neuropsychopharmacology in Waikolola, Hawaii December 8-13, 2001. Speakers at the symposium were James Anthony, Johns Hopkins University, Elliot Stein, Medical College of Wisconsin, Linda Porrino, Wake Forrest University, and Barry Everitt, Cambridge University.

In November 2001, Dorynne Czechowicz, M.D., DTR&D, represented the National Institute on Drug Abuse, at a DHHS meeting on International Drug Scheduling. The purpose of this meeting was to discuss the coordination of international scheduling activities among the various Federal agencies.

On November 9, 2001, Dr. Lisa Onken, DTR&D, gave a presentation entitled, “Behavioral Treatment Research at NIDA: Opportunities for Hispanic Researchers & Research,” at the meeting of the National Hispanic Science Network on Drug Abuse in Washington, D.C.

Dr. Eve Reider, Prevention Research Branch, DESPR, represented NIDA at the Center for Mental Health Services (CMHS)’, Substance Abuse and Mental Health Services Administration, Roundtable on Shared and Unique Perspectives of Evidence-Based Prevention Practices, on October 5, 2001 in Washington, D.C.

Dr. Reider represented NIDA at The National Prevention Coalition meeting held on October 9, 2001 held at the National Mental Health Association in Alexandria, Virginia.

Dr. Reider represented NIDA at the National Summit, When Terror Strikes: Addressing the Nation’s Mental Health and Substance Abuse Needs- Strengthening the Homeland through Recovery, Resilience and Readiness, sponsored by the U.S. Department of Health and Human Services (DHHS) and Substance Abuse and Mental Health Services Administration (SAMHSA). The summit was held November 14-16, 2001 in New York City. Dr. Reider was the reporter for a roundtable discussion entitled Research, Evaluation, and Best Practices.

Dr. Reider represented NIDA at an Interagency Juvenile Justice meeting held November 27, 2001 at Office of National Drug Control Policy (ONDCP) in Washington, D.C.

Drs. Liz Robertson, DESPR, and Suman Rao, OSPC, presented a seminar titled Principles of Prevention Research: An Update at the Community Anti-Drug Coalitions of American National Leadership Forum XII, on December 14, 2001, in Washington, D.C.

Arnold Mills, DESPR, attended the 53rd Annual Meeting of the American Society of Criminology held in Atlanta, Georgia November 7-10, 2001. He served as the discussant for one of the sessions entitled Drugs and Crime: A National Research Agenda.

Moira O’Brien, DESPR, gave a presentation on Brains, Behavior and Culture: Integrating Perspectives on Drug Abuse and Addiction in a National Research Program, and participated in a cross-NIH session on extramural research opportunities during the annual meeting of the American Anthropological Association in Washington, D.C. on December 1, 2001.

Dr. Kevin Conway, DESPR, attended the 53rd Annual Meeting of the American Society of Criminology held in Atlanta, Georgia November 7-10, 2001. He presented a paper entitled Substance Use Disorders, Psychopathology, and Reported Violence.

Dr. Conway organized a bioethics panel for the NIDA Genetics Consortium Meeting, December 4, 2001. The expert panelists discussed the ethics considerations surrounding issues third parties involved in human genetics research.

Dr. Jerry Flanzer, DESPR, gave two lectures, one on the state of health services research regarding adolescent drug abuse treatment and service delivery in 2001, the other on the directions for drug abuse health services research for the next decade at the Health Services Disparities Conference, Galveston, Texas, October 31-November 2, 2001.

Dr. Flanzer and Dr. Thomas Hilton, DESPR, represented NIDA at the International Oxford House Conference, Washington, DC, November 30, 2001.

Drs. Peter Delany and James Colliver of DESPR conducted briefings on the findings of the 2001 Monitoring the Future Study for the Department of Health and Human Services and the Office of National Drug Control Policy.

Dr. Colliver represented NIDA at the annual meeting of the Healthy People 2010 Consortium in Atlanta on October 19, 2001 and gave a presentation on progress toward substance abuse objectives.

Dr. Dionne J. Jones, CAMCODA, moderated a workshop entitled “Special Issues to Consider with Substance Abusers” and served as Discussant on a second workshop entitled, “Interventions for At Risk Minority Substance Abusing Women” at the American Public Health Association Annual Meeting in Atlanta, GA, October 22-25, 2001.

Dr. Jones chaired a NIDA-sponsored symposium entitled “Drug Abuse, HIV Risk, and HIV Disease in the Brain” at the Annual Meeting of the Society for Neuroscience in San Diego, CA, November 12-15, 2001.

Dr. Toni Shippenberg, IRP, was co-chair and presenter of a panel symposia entitled “Opioid-Induced Plasticity From Neuron To The Addict; New Perspectives for the Treatment of Drug Addiction” at the 2001 American College of Neuropharmacology Meeting, December 9-13, 2001, Waikoloa, Hawaii.

Dr. Amy Newman, IRP, presented two invited lectures entitled “ A Medicinal Chemistry Strategy in Drug-Abuse Research” and “Novel Probes for the Dopamine Transporter: In Search of a Cocaine-Abuse Therapeutic” at the Department of Chemistry, Northern Arizona University, Flagstaff, AZ, in November 2001.

[Office of the Director][Report Index][Next Report Section]

Archive Home | Accessibility | Privacy | FOIA (NIH) | Current NIDA Home Page
National Institutes of Health logo_Department of Health and Human Services Logo The National Institute on Drug Abuse (NIDA) is part of the National Institutes of Health (NIH) , a component of the U.S. Department of Health and Human Services. Questions? See our Contact Information. . The U.S. government's official web portal